Hypoglycemia - Pipeline Review, H1 2018

  • ID: 4457548
  • Report
  • 78 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Adocia SAS
  • Eli Lilly and Co
  • Novartis AG
  • Therakind Ltd
  • Vectura Group Plc
  • XOMA Corp
  • MORE
Hypoglycemia - Pipeline Review, H1 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Pipeline Review, H1 2018, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape.

Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, and irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity and cognitive dysfunction.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Hypoglycemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hypoglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 6, 5, 1 and 2 respectively.

Hypoglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoglycemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypoglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypoglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypoglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypoglycemia (Metabolic Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypoglycemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypoglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Adocia SAS
  • Eli Lilly and Co
  • Novartis AG
  • Therakind Ltd
  • Vectura Group Plc
  • XOMA Corp
  • MORE
Introduction

Hypoglycemia - Overview

Hypoglycemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hypoglycemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypoglycemia - Companies Involved in Therapeutics Development

Adocia SAS

Arecor Ltd

Eiger BioPharmaceuticals Inc

Eli Lilly and Co

Heptares Therapeutics Ltd

LATITUDE Pharmaceuticals Inc

Novartis AG

Rezolute Inc

Therakind Ltd

USV Pvt Ltd

Vectura Group Plc

XERIS Pharmaceuticals Inc

XOMA Corp

Zealand Pharma AS

Zucara Therapeutics Inc

Hypoglycemia - Drug Profiles

dasiglucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Hypoglycemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exendin-(9-39) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3143753 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3185643 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-900018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRL-2903 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide 1 to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RZ-358 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize GLP-1 Receptor for Congenital Hyperinsulinism and Hypoglycemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

terbutaline sulphate MR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XOMA-129 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypoglycemia - Dormant Projects

Hypoglycemia - Discontinued Products

Hypoglycemia - Product Development Milestones

Featured News & Press Releases

Jan 19, 2018: Zealand Pharma announces progress to Phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half

Dec 07, 2017: Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes

Nov 20, 2017: Adocia Reports Topline Results of BioChaperone Glucagon Phase 1 Study

Sep 21, 2017: JDRF Funds Zucara Therapeutics Approach to Preventing Hypoglycemia in People with Type 1 Diabetes

Jul 03, 2017: Zealand initiates first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes

Jun 16, 2017: Xeris Pharmaceuticals Announces New Results From Ready-To-Use Liquid Glucagon Clinical Development Program

Jun 12, 2017: Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego

Jun 10, 2017: Dasiglucagon (pINN) presentation at the 77th Scientific Sessions of the American Diabetes Association indicate use for treatment of severe hypoglycemia

Jun 06, 2017: Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients

Jun 01, 2017: Adocia Launches First-in-Man Clinical Study of BioChaperone Glucagon BioChaperone Glucagon, a ready-to-use stable aqueous formulat

Apr 18, 2017: Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia

Mar 23, 2017: XOMA provides update on pipeline program XOMA 358 at the 2017 ENDO Meeting

Mar 23, 2017: XOMA provides update on pipeline program XOMA 129 at the 2017 ENDO Meeting

Jan 31, 2017: XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery

Dec 13, 2016: Zealand initiates Phase IIa clinical trial with dasiglucagon in a dual-hormone artificial pancreas system from Beta Bionics

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hypoglycemia, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Hypoglycemia - Pipeline by Adocia SAS, H1

Hypoglycemia - Pipeline by Arecor Ltd, H1

Hypoglycemia - Pipeline by Eiger BioPharmaceuticals Inc, H1

Hypoglycemia - Pipeline by Eli Lilly and Co, H1

Hypoglycemia - Pipeline by Heptares Therapeutics Ltd, H1

Hypoglycemia - Pipeline by LATITUDE Pharmaceuticals Inc, H1

Hypoglycemia - Pipeline by Novartis AG, H1

Hypoglycemia - Pipeline by Rezolute Inc, H1

Hypoglycemia - Pipeline by Therakind Ltd, H1

Hypoglycemia - Pipeline by USV Pvt Ltd, H1

Hypoglycemia - Pipeline by Vectura Group Plc, H1

Hypoglycemia - Pipeline by XERIS Pharmaceuticals Inc, H1

Hypoglycemia - Pipeline by XOMA Corp, H1

Hypoglycemia - Pipeline by Zealand Pharma AS, H1

Hypoglycemia - Pipeline by Zucara Therapeutics Inc, H1

Hypoglycemia - Dormant Projects, H1

Hypoglycemia - Discontinued Products, H1

List of Figures

Number of Products under Development for Hypoglycemia, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Adocia SAS
  • Arecor Ltd
  • Eiger BioPharmaceuticals Inc
  • Eli Lilly and Co
  • Heptares Therapeutics Ltd
  • LATITUDE Pharmaceuticals Inc
  • Novartis AG
  • Rezolute Inc
  • Therakind Ltd
  • USV Pvt Ltd
  • Vectura Group Plc
  • XERIS Pharmaceuticals Inc
  • XOMA Corp
  • Zealand Pharma AS
  • Zucara Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll